61 results about "Macular edema" patented technology

A system, method and apparatus for anatomical mapping utilizing optical coherence tomography. In the present invention, 3-dimensional fundus intensity imagery can be acquired from a scanning of light back-reflected from an eye. The scanning can include spectral domain scanning, as an example. A fundus intensity image can be acquired in real-time. The 3-dimensional data set can be reduced to generate an anatomical mapping, such as an edema mapping and a thickness mapping. Optionally, a partial fundus intensity image can be produced from the scanning of the eye to generate an en face view of the retinal structure of the eye without first requiring a full segmentation of the 3-D data set. Advantageously, the system, method and apparatus of the present invention can provide quantitative three-dimensional information about the spatial location and extent of macular edema and other pathologies. This three-dimensional information can be used to determine the need for treatment, monitor the effectiveness of treatment and identify the return of fluid that may signal the need for re-treatment.

Provided is a method for treating ocular hypertension and glaucoma with reduced side effects such as keratoconjunctive disorders and macular edema, which comprises administering an ophthalmic composition comprising latanoprost as an active ingredient thereof to a subject in need of said treatment, wherein the ophthalmic composition contains substantially no benzalkonium chloride.

A system, method and apparatus for anatomical mapping utilizing optical coherence tomography. In the present invention, 3-dimensional fundus intensity imagery can be acquired from a scanning of light back-reflected from an eye. The scanning can include spectral domain scanning, as an example. A fundus intensity image can be acquired in real-time. The 3-dimensional data set can be reduced to generate an anatomical mapping, such as an edema mapping and a thickness mapping. Optionally, a partial fundus intensity image can be produced from the scanning of the eye to generate an en face view of the retinal structure of the eye without first requiring a full segmentation of the 3-D data set. Advantageously, the system, method and apparatus of the present invention can provide quantitative three-dimensional information about the spatial location and extent of macular edema and other pathologies. This three-dimensional information can be used to determine the need for treatment, monitor the effectiveness of treatment and identify the return of fluid that may signal the need for re-treatment.

The invention relates to the use of photodynamic therapy (PDT) to treat macular edemas, including DME, CRVO and BRVO. It provides an alternative to photocoagulation and the disadvantages associated therewith.

The present invention is directed to a method of inhibiting at least one of vascular leakage, inflammation and fibrosis in an animal by administering to the animal a vascular leakage inhibiting amount of a composition, wherein at a substantially higher amount the composition is effective in inhibiting angiogenesis, and wherein the anti-angiogenic activity of the composition is separate from the vascular leakage inhibiting activity of the composition. The animal experiencing at least one of vascular leakage, inflammation and fibrosis has a disease selected from the group consisting of diabetes, chronic inflammation, brain edema, arthritis, uvietis, macular edema, cancer, hyperglycemia, a kidney inflammatory disease, a disorder resulting in kidney fibrosis, a disorder of the kidney resulting in proteinuria, and combinations thereof. The composition capable of inhibiting at least one of vascular leakage, inflammation and fibrosis is selected from the group consisting of angiostatin, fragments of angiostatin, analogs or derivatives of angiostatin, kringle 5 of plasminogen, fragments of kringle 5 of plasminogen, analogs or derivatives of kringle 5 of plasminogen, pigment epithelium-derived factor, fragments of pigment epithelium-derived factor, analogs or derivatives of pigment epithelium-derived factor and combinations thereof.

The present invention relates to compounds which inhibit, regulate and / or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, macular edema, retinal ischemia, inflammatory diseases, and the like in mammals.

This invention is directed to prodrugs of rho kinase (ROCK) inhibitors. These prodrugs are in general the ester or the amide derivatives of the parent compounds. These prodrugs are often weak inhibitors of ROCK, but their parent compounds have good activities. Upon instillation into the eyes, the ester or the amide group of these prodrugs is rapidly hydrolyzed into alcohol, amine, or acid, and the prodrugs are converted into the active base compounds. The prodrugs of ROCK inhibitors provide several advantages such as delivery of higher concentrations of the active species into the target site and reduction of ocular discomfort. The invention is also directed to a method of treating ophthalmic diseases such as glaucoma, allergic conjunctivitis, macular edema, macular degeneration, and blepharitis, by administering an effective amount of a ROCK prodrug compound of Formula I to the eyes of the patient in need of.

The invention provides methods of treating macular edema in a patient that include determining whether the patient has been diagnosed with or has experienced symptoms of macular edema for a predetermined period of time. If the patient has been diagnosed with or has experienced symptoms of macular edema for a predetermined period of time, the method of treatment includes administering a therapeutically effective amount of an AED to the patient. If the patient has not been diagnosed with or has experienced symptoms of macular edema for a predetermined period of time, the method of treatment optionally includes treating the patient with a therapy other than an AED. The invention further provides methods of treating macular edema in a patient using methods of and devices for administering an AED.

A method for inhibiting VEGF stimulated endothelial cell growth, such as associated with macular degeneration, and VEGF stimulated capillary permeability, such as associated with macular edema are disclosed, particularly using the isozyme selective PKC inhibitor, (S)-3,4-[N,N'-1,1'-((2''-ethoxy)-3'''(O)-4'''-(N,N-dimethylamino)-butane)-bis-(3,3'-indoly 1)]-1(H)-pyrrole-2,5-dionehydrochloridesalt.

Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia / reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as uveitis, retinopathies or macular degeneration, macular edema or other vitreoretinal diseases, inflammatory diseases such as autoimmune diseases, vascular leakage syndrome, edema, or diseases involving leukocyte activation, transplant rejection, respiratory diseases such as asthma, adult or acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease, and the like.

A compound of the formula (I): R<1>-NH-X-Y-Z (I) wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a mammal, and the like.

The invention discloses a retinal macular edema multi-lesion image segmentation method. The method comprises the steps of collecting three-dimensional retinal OCT volume data and converting the three-dimensional retinal OCT volume data into a two-dimensional retinal OCT B scanning image; and inputting the two-dimensional retina OCT B scanning image into a trained coding and decoding attention network model to carry out retina macular edema multi-lesion joint segmentation, and obtaining a segmentation image result. According to the method, the coding and decoding attention network model is adopted for multi-lesion joint segmentation, richer global features can be obtained, simultaneous segmentation of retinal edema, subretinal effusion and pigment epithelium detachment multi-lesion in the retinal macular edema multi-lesion image is achieved, and a foundation is laid for follow-up lesion quantitative analysis.

Disclosed herein are compositions comprising one or more antibodies that specifically bind active plasma kallikrein (e.g., human plasma kallikrein) and methods of using such compositions for the treatment of retinal diseases, such as diabetic macular edema.

The invention discloses a deep learning-based early age-related macular lesion weakly supervised classification method, which comprises the following steps of 1, positioning a central concave positionof an eye fundus image by adopting a convolutional neural network, and intercepting a square area as a candidate area by taking the central concave position as an original point and taking a double-optic disc diameter as a side length; 2, judging whether glass membrane warts appear in the macular area or not by adopting a convolutional neural network, detecting the glass membrane warts in a weaksupervision manner, and judging whether the glass membrane warts appear in the fundus image or not; 3, performing linear interpolation by using the intermediate result of the step 2 to obtain a finalpixel-level focus marking result. According to the algorithm, a weak supervision method is adopted for classifier training and detection, only whether the fundus image has vitreous condyloma information or not needs to be provided, the classifier can be trained without specific position information, correct classification of the early-stage age-related macular lesion fundus image is achieved, andthe algorithm can effectively save the cost of marking training data while the precision is guaranteed.

The present invention is a method of the present invention screens a patient with macular edema associated with visual loss for implantation of a sustained release drug-delivery implant that is less invasive than implanting a drug-delivery implant and is minimally invasive. The method comprises injecting a first steroid, eg. triamcinolone acetonide, having anti-inflammatory activity as a bolus into a patient's eye. Patients that experience a reduction in swelling in the retina (typically the macula and preferably the fovia) and improved vision are identified as candidate patients. Candidate patients are patients that are more likely to benefit from the implantation of a sustained release drug-delivery implant into the eye containing a second steroid, for example fluocinolone acetonide.

Provided are methods, pharmaceutical formulations and kits thereof for the treatment and / or prevention of conditions mediated by neovascularization, abnormal angiogenesis, vascular permeability, or combinations thereof, of posterior and / or anterior tissues and fluids of the eye, including conditions associated with proliferative retinopathies, for example, diabetic retinopathy, age-related maculopathy, retinopathy of prematurity, retinopathy associated with macular edema, or retinopathy associated with sickle cell disease, using the topical administration of mecamylamine or a pharmaceutically acceptable salt thereof to the eye. Methods of preparing the pharmaceutical formulations are also provided.

We have identified classes of kallikrein inhibitors as compounds that are useful in the reduction of vascular permeability (e.g., retinal vascular permeability and cerebral vascular permeability) and astrocyte activation. Diseases and conditions associated with increased vascular permeability include diabetic retinopathy, hemorrhagic stroke, and macular edema. Diseases and conditions associated with astrocyte activation include Alzheimer's disease, multiple sclerosis, Parkinson's disease, amyotrophic lateral sclerosis, Creutzfeldt-Jakob disease, stroke, epilepsy, and brain trauma.

A compound of the formula (I), (II), (III) or (IV): wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a subject, and the like.

The embodiment of the application discloses an information obtaining method and device; one embodiment of the method comprises the following steps: obtaining an eyeground image; importing the eyeground image into a pre-trained pathology grading model for processing, thus obtaining pathology grading information, wherein the pathology grading model is used for representing a corresponding relation between a pathology area image contained by the eyeground image and the pathology grading information, and the pathology grading information comprises retina pathology grading information and / or maculalutea oedema grading information; using the pathology grading information to form output information. The method can obtain the retina pathology grading information and the macula lutea oedema grading information from the eyeground image, can fully utilize the correlation between the retina pathology and the macula lutea oedema in the diagnosis process, thus effectively improving the retina pathology grading and macula lutea oedema grading precision in the computer auxiliary diagnosis process.

The present invention relates to methods, devices, and compositions for treating ocular disorders such as uveitis, macular edema associated with uveitis, and diabetic macular edema. For example, the methods include treatment of subjects having macular edema associated with non-infectious uveitis, or diabetic macular edema, by administering to the subjects a triamcinolone composition via non-surgical administration to the suprachoroidal space (SCS) of the eye.

A retinoscopic device, technique and scale for estimating the reflectance of the macula pigment optical density (MPOD) in normal and abnormal eyes in order to detect early pathology of the retinal pigment epithelium and photoreceptors thus screening for macular pathology the most prevalent of which is Age-related Macular Degeneration (AMD) and retinal edema and cystoid macular edema post cataract surgery.

This invention relates to CXCR4 inhibitors and their use in treating and / or preventing a variety of angiogenic, microvascular and ocular disorders including primary indications for diabetic retinopathy, macular degeneration (such as wet or neovascular age-related macular degeneration (AMD) and dry or atrophic AMD), macular edema, and secondary indications for inhibiting tumor vascularization, and corneal and iris neovascularization.

The invention provides a macular edema lesion area segmentation method based on a deep neural network. The macular edema lesion area segmentation method comprises the steps of acquiring an OCT image of an fundus of a macular edema patient; and inputting the OCT image into a trained deep neural network segmentation model to obtain a focus area on the OCT image of the fundus of the macular edema patient. The OCT image is input into the trained deep neural network segmentation model to obtain the focus area on the OCT image of the fundus of the macular edema patient. Compared with the prior art,a lot of manpower and material resources are saved. Meanwhile, a focus area on the OCT image of the fundus of the macular edema patient is acquired through the trained deep neural network segmentationmodel. The problem that the evaluation error of macular edema is large due to the fact that at present, due to the fact that OCT image noise is large and experience differences between doctors are large, sketching results of different doctors are often large in difference can be solved.